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Thymolipomas are rare, benign thymic lesions (2%-9% ofthymic tumors), consisting of adipose tissue inside thethymus, which is slow growing1 and has scarce local andsystemic manifestations (50% diagnosed in routine radi-
ologic studies).2 Myasthenia gravis (MG) is generally associated
with and present in up to 30% of thymomas.1 However, association
with thymolipomas is uncommon, with just 15 cases reported in
the English-speaking literature (Medline 1967-August 2000).2-14
We report 3 new cases of this uncommon association and
review the literature.
Clinical Summary
Two patients were women, and one was a man. The clinical pre-
sentation was general weakness, which increased during the course
of the day. The patients had vertical diplopia and weakness of jaw
movement. Two patients had dysphagia, more noticeably after eat-
ing, and one had dysphonia during conversations, which improved
with rest.
In the 3 patients the physical exploration revealed a steady loss
of strength on repeated movement, and the edrophony test results
were positive. In 2 patients the antiacetylcholine receptor and anti-
striated muscle antibody levels were positive. Chest radiography
was within normal limits. Mediastinal computed tomography
showed no abnormalities in 1 patient. In the other 2 patients the
computed tomograms showed a lesion at the thymus that was com-
patible with a diagnosis of thymoma. Electromyography with
repetitive nerve stimulation, done in 2 patients, revealed a decrease
of more than 20% in 1 patient and more than 15% in the other
patient.
The treatment was implemented with anticholinesterases (pyri-
dostigmine, 60 mg/6 hours) and steroids (prednisone, 60 mg/d),
which failed to achieve total remission of the symptoms in 2
patients. The patients underwent thymectomy which extended to
the whole of the mediastinal fat. Histologic study revealed thy-
molipomas. During the postoperative period, 1 patient had a
venous thrombosis that required anticoagulation.
After the operation, the MG symptoms improved partially, and
the MG was controlled with small doses of corticosteroids and, in
2 patients, with small doses of anticholesterases. Twelve months
after the thymectomy, 1 patient had dyspnea, and treatment was
reimplemented with pyridostigmine (60 mg/8 hours) and pred-
nisone (20 mg/d), requiring hospital admission. Currently, 10 years
after the operation, the patient’s clinical symptoms are partially
controlled with this medication. In the other patients currently,
after 9 and 10 years, the symptoms are being partially controlled
with pyridostigmine (30 mg/8 hours) and prednisone (15 mg/d).
Comment
The association of MG with thymolipomas is uncommon, and it is
regarded by some authors as a simple epiphenomenon, although
the fact that symptoms regress in most patients after thymectomy
suggests that there is a relationship. The pathogenesis of thy-
molipoma is not clear, and there are currently 4 theories.2,9 One of
the theories considers that the thymolipoma is a fatty involution of
a thymoma, and therefore the thymolipomas would be true thymo-
mas. Furthermore, the coexistence of thymolipoma with MG, other
autoimmune diseases, or neoplastic conditions suggests that thy-
moma and thymolipoma are at least related tumors.
The patients with thymolipoma and MG differ from patients
without MG in 2 ways: (1) thymolipomas with MG appear in older
patients (20-30 years vs 40-50 years)12 and (2) mean thymolipoma
weights are lower in patients with MG (100 g vs 1000 g). This can
be explained because thymolipomas without MG are usually diag-
nosed when they are large.9
Treatment for MG is initially medical, with anticholinesterases
and corticosteroids and occasionally plasmapheresis. The surgical
treatment of MG consists of thymectomy, which can be performed
through a vertical sternotomy or cervicotomy; the former is rec-
ommended because it makes it easier to extend the thymectomy to
the whole of the mediastinal fat, even with removal of both medi-
astinal pleurae. Extended thymectomy is currently the recom-
mended treatment for MG.
Follow-up data are not easily interpretable because the report-
ed postoperative periods are short, although thymectomy always
leads to improvement (Table 1). However, a relapse of MG
occurred in 4 (26.7%) of the 15 published cases2-14 but with such
short follow-up periods in most cases that it is impossible to assess
the long-term results. Our series has a long follow-up period (>9
years). Two of the patients have shown a marked improvement, and
the third, despite occasional relapses of MG, has also shown
improvement. Only one of the patients, presented by Pan and col-
leagues,6 had total remission of the MG after thymectomy.
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Although thymectomy does not usually resolve the clinical fea-
tures of MG associated with thymolipoma, it does considerably
improve symptoms and allows them to be controlled with a small-
er dose of anticholinesterases and corticosteroids.
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TABLE 1. Cases of thymolipomas with MG reported in the English-speaking literature
Preoperative Thymolipoma Postoperative Follow-up
Case No. Author Age (y) Sex evolution weight evolution Relapse time
1 Reintgen and colleagues3 60 Male 1 y 100 g Improvement No 3 mo
2 Otto and colleagues4 56 Male 4 y 93 g Improvement Yes (3 wk) 1 mo
3 Mikkelsen5 61 Male 29 mo 65 g Improvement Yes (7 mo) 8 mo
4 Pan and colleagues6 62 Female 7 mo 90 g Complete remission No 24 mo
5 Pan and colleagues6 54 Female 6 y — Improvement Yes (2 mo) 18 mo
6 Olanow and colleagues7 62 ? 16 mo — Improvement No 40 mo
7 Alfaro8 31 Male 10 y 10 g Improvement No 6 mo
8 Le Marc´hadour and colleagues9 52 Male 2 y 185 g Improvement No 18 mo
9 Moran and colleagues2 — — — — — — —
10 Moran and colleagues2 — — — — — — —
11 Toyama and colleagues10 48 Male 2 mo 680 g Improvement Yes (–) —
12 Sirpal and colleagues11 60 Female — — Improvement — —
13 Verbist and colleagues12 29 Male 4 y 340 g Improvement No 2 mo
14 Takamori and colleagues13 29 Female — — Improvement — —
15 Hayashi and colleagues14 29 Female — — Improvement — —
16 Our series 58 Female 7 mo 45 g Improvement Yes (12 mo) 10 y
17 Our series 63 Female 6 mo 60 g Improvement No 10 y
18 Our series 59 Male 2 y 70 g Improvement No 9 y
